Our Approach to Corporate Responsibility At Ionis, we work with a sense of urgency to discover, develop and deliver medicines to create a better future for people with serious diseases. We believe operating responsibly and sustainably creates long-term value for our company and our stakeholders. Every day we work to create a positive impact for […]
What is the Ionis Neurology Young Investigator Grant? Ionis Pharmaceuticals is pleased to announce the Ionis Neurology Young Investigator Grant (YIG). This grant was recently created by the Division of Neurology within Medical Affairs to advance high-quality research in the field of Alexander Disease by early career investigators. Ionis is dedicated to developing clinicians and […]
What is the Ionis Young Investigator Grant (YIG)? Ionis Pharmaceuticals is pleased to announce the Ionis YIG. This grant was recently created within Medical Affairs to recognize early career investigators who are performing high quality research in HAE. Ionis values developing clinicians and scientists who will influence the field and support new research for years […]
Our DEI Journey Since Ionis’ inception in 1989, our founders valued diversity and noted in our original Culture Statement that “prejudicial barriers to human potential and productivity are foreign to our values.” That language remains the foundation or Our DEI Purpose and continues to drive the DEI progress in our organziation. In 2020, our leadership […]
Olezarsen met the primary endpoint with a statistically significant reduction in triglyceride levels versus placebo First study to show an absolute reduction in acute pancreatitis in FCS patients, with olezarsen 80 mg monthly dose reducing events by 100 percent Olezarsen demonstrated a favorable